NRC Health (National Research Corporation) — FY2021 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended December 31, 2021; it does not provide standalone fourth-quarter results. NRC Health sells primarily subscription-based analytics, patient-experience and engagement, market-insights, transparency, and healthcare-governance services. Most revenue is generated in the United States, and approximately 93% of 2021 revenue came from subscription services recognized over time.
Financial performance and position
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $147.954 million | $133.277 million | +11.0% |
| Operating income | $50.270 million | $42.677 million | +17.8% |
| Operating margin | 34.0% | 32.0% | +2.0 percentage points |
| Net income | $37.466 million | $37.260 million | +0.6% |
| Diluted EPS | $1.46 | $1.45 | +0.7% |
| Cash from operating activities | $46.344 million | $40.636 million | +14.0% |
| Recurring contract value | $150.937 million | $145.079 million | +4.0% |
At year-end, cash and cash equivalents were $54.361 million, compared with $34.690 million a year earlier. Working capital surplus was $33.3 million, up from $22.4 million. The term loan balance was $26.6 million; there were no borrowings on the $30 million revolving facility or the $15 million delayed-draw facility. The term loan carries a 5% fixed rate, with monthly installments and a May 2025 maturity. The company reported compliance with its debt covenants.
Capital spending was $5.5 million in 2021. The company expects further headquarters renovation costs of approximately $15 million in 2022 and $7 million in 2023. Dividends declared totaled $12.2 million in 2021; $9.2 million was paid during the year and $3.0 million in January 2022. Share repurchases totaled $4.6 million during 2021.
Changes versus the prior comparable period
- Revenue growth reflected new customer sales and increased sales to existing clients, alongside recovery from some COVID-related client reductions in 2020.
- Operating income and margin improved as subscription-model operating leverage and cost discipline more than offset higher expenses. SG&A rose 13.1%, including higher compensation, professional-service, technology, and public-company costs.
- Net income was nearly flat despite higher operating income, as the income-tax provision rose to $11.2 million from $4.2 million. The effective tax rate increased to 22.9% from 10.1%, primarily because of smaller tax benefits from share-based compensation and higher state taxes.
- Recurring contract value growth slowed to 4.0% from 6.1%. Management cited stronger retention, but lower sales amid pandemic-related selling difficulties and sales-force turnover, as well as discontinuation of certain legacy offerings while focusing on digital core solutions.
- Cash from operations increased, supported by collections and deferred-revenue timing. The company acquired PatientWisdom in January 2021 for $5.0 million in cash, including $2.0 million paid in January 2022.
Outlook, risks, and unusual items
Management expects 2022 revenue growth to align more closely with recurring contract value growth and cautioned that recent revenue and earnings growth should not be viewed as indicative of future results. It believes available cash, borrowing capacity, and operating cash flows will meet expected needs for the foreseeable future. No numerical earnings or revenue guidance was provided.
- COVID-19 and execution: Management reported no significant financial impact from COVID-19 in 2020 or 2021, but client budget pressure, service reductions, third-party disruptions, and uncertainty remain. Higher associate attrition in 2021 may raise recruiting and retention costs and affect sales and service delivery.
- Cybersecurity: A February 2020 cyberattack temporarily suspended services. Insurance recoveries limited its financial effect, but future attacks, data breaches, outages, or privacy-law violations could cause client losses, costs, litigation, or regulatory exposure.
- Commercial risks: Annual contracts are generally cancelable on short notice; healthcare-sector concentration, competition, pricing pressure, client consolidation, and reliance on third-party data and service providers could affect results. The ten largest clients represented 14% of revenue in 2021.
- Canada and currency: NRC plans to close its Canadian office after a major customer contract ends in September 2022. The company recorded a $714,000 Canadian goodwill impairment in 2020 and expects no foreign-currency exposure after the planned office closure.
- Capital allocation and control: Renovation spending is a material planned cash requirement. Trusts and other entities associated with the CEO’s family held approximately 52.4% of shares as of February 25, 2022, giving them substantial voting influence.
- Other items: The company recorded a $324,000 impairment on a Seattle office lease right-of-use asset in 2021. Management said pending legal matters were not expected to materially affect financial position, results, or liquidity. Unrecognized tax benefits were $1.1 million at year-end.
KPMG issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal control were effective. The auditor identified sufficiency of evidence over key terms in new and modified subscription contracts as a critical audit matter, given the dependence of revenue calculations on data entered into the company’s IT system.
Important facts for investors to verify
- Whether 2022 revenue growth tracks the 4.0% recurring-contract-value growth rate, and how renewals, downsells, and new sales develop.
- Whether higher 2021 retention persists and whether sales-force turnover and associate attrition moderate.
- Cash generation after planned $22 million of headquarters renovation costs over 2022–2023, dividends, and debt service.
- Completion and financial consequences of the Canada office closure and the major customer contract ending in September 2022.
- Cybersecurity controls and remediation following the 2020 incident, and the accuracy of key subscription-contract data used for revenue recognition.
- Future tax rates and tax benefits, including the effect of share-based compensation and uncertain tax positions.